Ceres Inc (CERE): Price and Financial Metrics
GET POWR RATINGS... FREE!
CERE Stock Price Chart Interactive Chart >
CERE Price/Volume Stats
|Current price||$27.25||52-week high||$46.16|
|Prev. close||$26.96||52-week low||$12.01|
|Day high||$27.45||Avg. volume||458,010|
|50-day MA||$30.25||Dividend yield||N/A|
|200-day MA||$31.59||Market Cap||4.03B|
Ceres Inc (CERE) Company Bio
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies.
Most Popular Stories View All
CERE Latest News Stream
|Loading, please wait...|
CERE Latest Social Stream
View Full CERE Social Stream
Latest CERE News From Around the Web
Below are the latest news stories about Cerevel Therapeutics Holdings Inc that investors may wish to consider to help them evaluate CERE as an investment opportunity.
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT – Research Report), Stealth Biotherapeutics (MITO – Research Report) and Cerevel Therapeutics Holdings (CERE – Research Report) with bullish sentiments. Corcept Therapeutics (CORT) H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics today and set a price target of $29.00. The company's shares closed last Tuesday at $20.31. According to TipRanks.
Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter 2021 financial results on Tuesday, March 1, 2022, before the U.S. financial markets open. Management will host a conference call to discuss fourth quarter 2021 financial results and recent business updates on Tuesday, March 1, 2022 at 8:00 a.m. ET. To access the call, ple
Cerevel Therapeutics Holdings Inc's (NASDAQ: CERE) 7.5 mg twice daily and the 25 mg twice-daily doses of darigabat demonstrated clinically meaningful and statistically significant anxiolytic activity in healthy volunteers compared with placebo. After eight days of treatment, the darigabat 7.5 mg and 25 mg twice-daily doses demonstrated a 3.9 point and 4.5 point placebo-adjusted improvement, respectively, on the primary endpoint of the Panic Symptoms List (PSL-IV) total score. The positive contro
Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety
In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic Symptoms List score after eight days of dosing compared with placebo Darigabat was generally well-tolerated; resulted in no serious adverse events and no treatment-related discontinuations in the trialCerevel intends to advance development of darigabat in anxiety-related disordersConference call and webcast scheduled for today
Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented
Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia Company expects to initiate Phase 2 program for emraclidine in schizophrenia by the middle of 2022, with data expected in the first half of 2024 Phase 1 trial for darigabat in acute anxiety completed; data is expected in the next several weeks Phase 2a data for CVL-871 in dementia-related apathy now expected 1H 2023; delayed from 2H 2022, due in
CERE Price Returns